Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology
Disease Category: Lung Cancer
Trial Information
Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer (NSCLC)
Randomized, Open Label, Phase 3 Trial Of Erlotinib Alone Or In Combination With Cp 751,871 In Patients With Advanced Non Small Cell Lung Cancer Of Non Adenocarcinoma Histology
Patient Inclusion Criteria
- Non small cell lung cancer with a primary histology of squamous cell, large cell or adenosquamous carcinoma. At least 1 measurable lesion, as defined by RECIST.
Patient Exclusion Criteria
- Primary NSCLC adenocarcinoma and its subtypes or unknown/unspecified histology.
- Prior Erlotinib therapy.
- Prior anti IGF IR based investigational therapy.
Cathy Spears, Director Research department
St. Francis Hospital and Health Centers
1500 N Albany Street, Suite 1001
Beech Grove, IN 46107
Phone: 317-782-7819
Fax: 317-782-7828
EMail: cathy.spears@ssfhs.org
View Google Map
If you would like to learn more about participating in this study, please send an e-mail message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these
trials.
